Country: Canada
Language: English
Source: Health Canada
GADOXETATE DISODIUM
BAYER INC
V08CA10
GADOXETIC ACID
181.43MG
SOLUTION
GADOXETATE DISODIUM 181.43MG
INTRAVENOUS
5ML/7.5ML/10ML
Ethical
OTHER DIAGNOSTIC AGENTS
Active ingredient group (AIG) number: 0152685001; AHFS:
APPROVED
2010-01-14
_ _ _PRIMOVIST Product Monograph _ _Page 1 of 29 _ PRODUCT MONOGRAPH PRIMOVIST ® gadoxetate disodium injection 181.43 mg/mL (0.25 mmol/mL) Intravenous contrast enhancement agent for magnetic resonance imaging (MRI) For Professional Use Only Distributed and Imported by: Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6 http://www.bayer.ca Date of Revision: May 12, 2017 Submission Control No: 202821 © 2017, Bayer Inc. ® TM see www.bayer.ca/tm-mc. All other trademarks are the property of their respective owners. _ _ _PRIMOVIST Product Monograph _ _Page 2 of 29 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................13 ACTION AND CLINICAL PHARMACOLOGY ............................................................13 STORAGE AND STABILITY ..........................................................................................15 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................15 PART II: SCIENTIFIC INFORMATION ................................................................................16 PHARMACEUTICAL IN Read the complete document